Given the deleterious influence of aberrant mTOR activation in several genetic forms of autism spectrum disorders (Ehninger et al, 2008; Ehninger & Silva, 2011; Huber et al, 2015; Sato, 2016; Ryskalin et al, 2018), administration of 5‐HT6 receptor antagonists as soon as adolescence might profitably be evaluated in autism. This evidence concerns the gene MTOR and autism spectrum disorder.